0000950170-24-099982.txt : 20240822 0000950170-24-099982.hdr.sgml : 20240822 20240822192358 ACCESSION NUMBER: 0000950170-24-099982 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240821 FILED AS OF DATE: 20240822 DATE AS OF CHANGE: 20240822 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lian Brian CENTRAL INDEX KEY: 0001614578 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 241233187 MAIL ADDRESS: STREET 1: C/O SEELOS THERAPEUTICS, INC. STREET 2: 300 PARK AVENUE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-08-21 0001607678 Viking Therapeutics, Inc. VKTX 0001614578 Lian Brian C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 true true false false President & CEO true Common Stock, par value $0.00001 per share 2024-08-21 4 M false 1000 7.77 A 2355927 D Common Stock, par value $0.00001 per share 2024-08-21 4 S false 1000 69.90 D 2354927 D Stock Option (Right to Buy) 7.77 2024-08-21 4 M false 1000 0 D 2021-01-03 2030-01-03 Common Stock 1000 231130 D The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. 25% of the shares subject to the option vested on each anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2024-08-22